Artwork

Indhold leveret af The Lancet Group. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af The Lancet Group eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !

Edouard Louis on the SPARE trial of infliximab or immunosuppressant withdrawal in Crohn’s disease

21:30
 
Del
 

Manage episode 354865018 series 2891295
Indhold leveret af The Lancet Group. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af The Lancet Group eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Edouard Louis (University Hospital CHU of Liège) discusses the SPARE randomised controlled trial of infliximab or concomitant immunosuppressant withdrawal in patients with Crohn’s disease.
Read the full article:
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE)

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

  continue reading

84 episoder

Artwork
iconDel
 
Manage episode 354865018 series 2891295
Indhold leveret af The Lancet Group. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af The Lancet Group eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Edouard Louis (University Hospital CHU of Liège) discusses the SPARE randomised controlled trial of infliximab or concomitant immunosuppressant withdrawal in patients with Crohn’s disease.
Read the full article:
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE)

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

  continue reading

84 episoder

Tüm bölümler

×
 
Loading …

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Hurtig referencevejledning

Lyt til dette show, mens du udforsker
Afspil